Blood Thinner Study for Irregular Heartbeat
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have atrial fibrillation (irregular heartbeat) that is not caused by a temporary reversible condition
- You need long-term blood thinner treatment to prevent stroke and blood clots
- You have at least one risk factor for stroke (like age 65+, high blood pressure, diabetes, heart failure, or prior stroke)
- You do not have a mechanical heart valve or moderate-to-severe mitral stenosis (valve disease)
- You have not had a stroke in the past 2 days or had recent heart ablation or LAA closure procedure
- Your kidneys are working adequately (not on dialysis and eGFR ≥15)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This trial tests a new medication to prevent strokes and blood clots in people with atrial fibrillation (an irregular heartbeat) who cannot safely take standard blood thinners. The drug works by blocking a different clotting factor, which may lower bleeding risks.
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
This trial compares two ways to manage blood-thinning medications after a successful atrial fibrillation ablation, specifically for people who also have a heart stent. It aims to find the safest and most effective strategy to prevent strokes and bleeding.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
This Phase 3 study tests whether a blood thinner (apixaban) can help prevent another stroke and support recovery after you’ve had a brain bleed. You would be assigned to a treatment group, and the study checks safety and whether strokes can be reduced without causing dangerous bleeding.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.